Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Zamicastat and Furosemide
NCT07173738Phase 1Completed
- Sponsor
- BIAL
- Start
- Jun 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zamicastat in pulmonary arterial hypertension (PAH), sponsored by BIAL. Primary endpoints: Maximum observed concentration up to 3 months, Time to Cmax up to 3 months and 4 more. Started Jun 2018; status: completed.
02
Drugs
zamicastat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07173738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07173738.